LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced participation at the following conferences:
- The 6th Annual William Blair and Maidstone Life Sciences conference “Cancer Immunotherapy: A Long-Awaited Reality Conference” at the Apella, Event Space Alexandria Center in New York, NY on Thursday, March 31, 2016. Robert B. Stein, M.D., Ph.D., President, R&D will moderate three panels and present at a session titled “Integrated Approach to Optimizing Cancer Immunotherapy.”
- Cancer Advance Boston at Harvard Medical School – Joseph B. Martin Conference Center in Boston, MA on Monday, April 4, 2016. Dr. Stein will moderate a panel at 4:10 pm titled “Combination Therapy.”
- Jefferies Immuno-Oncology Summit at the Boston Harbor Hotel in Boston, MA on Thursday, April 7, 2016. Dr. Stein will present at 1:45 pm.
Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach to target identification and validation, and for the discovery, development and manufacturing of monoclonal antibodies that modulate targets of interest. The company’s broad portfolio of novel checkpoint modulator and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. Agenus’ heat shock protein-based vaccine, Prophage™, has successfully completed Phase 2 studies in newly-diagnosed glioblastoma. The company is collaborating with Merck and Incyte to discover and develop multiple checkpoint modulators. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the Company’s upcoming presentations. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of Agenus’ Form 10-K filed with the Securities and Exchange Commission on March 15, 2016. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.